Cargando…
Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair
A wide diversity of perturbations of the central nervous system (CNS) result in structural damage to the neuroarchitecture and cellular defects, which in turn are accompanied by neurological dysfunction and abortive endogenous neurorepair. Altering intracellular signaling pathways involved in inflam...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412282/ https://www.ncbi.nlm.nih.gov/pubmed/28338622 http://dx.doi.org/10.3390/ijms18040696 |
_version_ | 1783232963096346624 |
---|---|
author | Knott, Eric P. Assi, Mazen Rao, Sudheendra N. R. Ghosh, Mousumi Pearse, Damien D. |
author_facet | Knott, Eric P. Assi, Mazen Rao, Sudheendra N. R. Ghosh, Mousumi Pearse, Damien D. |
author_sort | Knott, Eric P. |
collection | PubMed |
description | A wide diversity of perturbations of the central nervous system (CNS) result in structural damage to the neuroarchitecture and cellular defects, which in turn are accompanied by neurological dysfunction and abortive endogenous neurorepair. Altering intracellular signaling pathways involved in inflammation and immune regulation, neural cell death, axon plasticity and remyelination has shown therapeutic benefit in experimental models of neurological disease and trauma. The second messengers, cyclic adenosine monophosphate (cyclic AMP) and cyclic guanosine monophosphate (cyclic GMP), are two such intracellular signaling targets, the elevation of which has produced beneficial cellular effects within a range of CNS pathologies. The only known negative regulators of cyclic nucleotides are a family of enzymes called phosphodiesterases (PDEs) that hydrolyze cyclic nucleotides into adenosine monophosphate (AMP) or guanylate monophosphate (GMP). Herein, we discuss the structure and physiological function as well as the roles PDEs play in pathological processes of the diseased or injured CNS. Further we review the approaches that have been employed therapeutically in experimental paradigms to block PDE expression or activity and in turn elevate cyclic nucleotide levels to mediate neuroprotection or neurorepair as well as discuss both the translational pathway and current limitations in moving new PDE-targeted therapies to the clinic. |
format | Online Article Text |
id | pubmed-5412282 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-54122822017-05-05 Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair Knott, Eric P. Assi, Mazen Rao, Sudheendra N. R. Ghosh, Mousumi Pearse, Damien D. Int J Mol Sci Review A wide diversity of perturbations of the central nervous system (CNS) result in structural damage to the neuroarchitecture and cellular defects, which in turn are accompanied by neurological dysfunction and abortive endogenous neurorepair. Altering intracellular signaling pathways involved in inflammation and immune regulation, neural cell death, axon plasticity and remyelination has shown therapeutic benefit in experimental models of neurological disease and trauma. The second messengers, cyclic adenosine monophosphate (cyclic AMP) and cyclic guanosine monophosphate (cyclic GMP), are two such intracellular signaling targets, the elevation of which has produced beneficial cellular effects within a range of CNS pathologies. The only known negative regulators of cyclic nucleotides are a family of enzymes called phosphodiesterases (PDEs) that hydrolyze cyclic nucleotides into adenosine monophosphate (AMP) or guanylate monophosphate (GMP). Herein, we discuss the structure and physiological function as well as the roles PDEs play in pathological processes of the diseased or injured CNS. Further we review the approaches that have been employed therapeutically in experimental paradigms to block PDE expression or activity and in turn elevate cyclic nucleotide levels to mediate neuroprotection or neurorepair as well as discuss both the translational pathway and current limitations in moving new PDE-targeted therapies to the clinic. MDPI 2017-03-24 /pmc/articles/PMC5412282/ /pubmed/28338622 http://dx.doi.org/10.3390/ijms18040696 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Knott, Eric P. Assi, Mazen Rao, Sudheendra N. R. Ghosh, Mousumi Pearse, Damien D. Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair |
title | Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair |
title_full | Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair |
title_fullStr | Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair |
title_full_unstemmed | Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair |
title_short | Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair |
title_sort | phosphodiesterase inhibitors as a therapeutic approach to neuroprotection and repair |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5412282/ https://www.ncbi.nlm.nih.gov/pubmed/28338622 http://dx.doi.org/10.3390/ijms18040696 |
work_keys_str_mv | AT knottericp phosphodiesteraseinhibitorsasatherapeuticapproachtoneuroprotectionandrepair AT assimazen phosphodiesteraseinhibitorsasatherapeuticapproachtoneuroprotectionandrepair AT raosudheendranr phosphodiesteraseinhibitorsasatherapeuticapproachtoneuroprotectionandrepair AT ghoshmousumi phosphodiesteraseinhibitorsasatherapeuticapproachtoneuroprotectionandrepair AT pearsedamiend phosphodiesteraseinhibitorsasatherapeuticapproachtoneuroprotectionandrepair |